Tazorac may be applied to any affected skin area, but using it on large surface areas increases the risk of irritation. Most clinicians recommend treating the face first, then gradually extending to the trunk or limbs if tolerated.
Stop using the product immediately, rinse the area gently with water, apply a fragrance-free moisturizer, and contact your prescriber. They may reduce the strength or advise an alternate treatment schedule.
Concurrent use can intensify skin irritation. If you wish to use both, space applications by at least 6 hours and monitor your skin closely. Your dermatologist can suggest a compatible regimen.
Yes. Tazarotene can increase photosensitivity. Apply a broad-spectrum sunscreen (SPF 30 or higher) each morning and limit direct sun exposure while using the medication.
Most patients notice a reduction in inflammatory lesions within 4-6 weeks, while comedonal improvement may take up to 12 weeks. Consistent nightly use is essential for optimal results.
No. Tazarotene is contraindicated in pregnancy due to a high risk of birth defects. Effective contraception is required during treatment and for at least 1 month after the last application.
The 5 % formulation delivers a higher concentration of tazarotene, providing a stronger therapeutic effect but also a greater potential for irritation. Your prescriber selects the strength based on disease severity and skin tolerance.
Moisturising is recommended to alleviate dryness and scaling. Apply a non-comedogenic moisturizer after Tazorac has fully absorbed (approximately 15 minutes).
No. Applying Tazorac to open wounds, abrasions, or severely inflamed skin can cause excessive irritation and should be avoided.
Concurrent use of two systemic or topical retinoids can increase the risk of severe skin irritation and systemic side effects. Your dermatologist will usually advise against using them together.
Tazorac is a topical medication marketed in the United Kingdom that contains the active ingredient tazarotene. It belongs to the skin-care category of prescription medicines and is supplied in a tube formulation with strengths of 1 % and 5 %. The product is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use on the skin under the supervision of a qualified healthcare professional.
Tazarotene is a synthetic retinoid, a class of compounds chemically related to vitamin A. When applied to the skin, it binds to nuclear retinoic acid receptors (RAR-α, RAR-β, and RAR-γ). Activation of these receptors influences gene expression in skin cells, leading to:
These actions collectively help treat conditions characterised by abnormal skin cell growth and inflammation.
In the United Kingdom, Tazorac is approved for the following indications:
The medication is prescribed for patients whose disease has not responded adequately to milder topical treatments. It is generally used after a dermatologist has evaluated the severity and extent of the skin condition.
Research literature reports that tazarotene may improve signs of photo-aged skin (sun-induced fine lines, mottled pigmentation, and rough texture). While these findings stem from controlled studies, the indication is not approved by the MHRA.
Disclaimer: Off-label use of Tazorac for photo-aging should only be undertaken under the supervision of a qualified healthcare provider who can assess individual risk and benefit.
General advice: Always inform your healthcare provider of all prescription medicines, over-the-counter products, supplements, and herbal remedies you are using before starting Tazorac.
This article provides educational information about Tazorac and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
